Literature DB >> 11060507

Apolipoprotein E phenotype alone does not influence survival in Alzheimer's disease: a population-based longitudinal study.

A M Koivisto1, P Lempiäinen, K Koivisto, E L Helkala, L Mykkänen, J Kuusisto, K Kervinen, Y A Kesäniemi, M Laakso, H Soininen.   

Abstract

Apolipoprotein E4 (ApoE4) phenotype is a known risk factor for development of Alzheimer's disease (AD). Contradictory results exist concerning the role of ApoE4 in the rate of decline and mortality in AD. Conflicting findings have also been reported about ApoE and gender interactions with respect to survival. We examined the survival of subjects with AD and non-AD controls with respect to ApoE phenotype and gender in a population-based longitudinal study. Cognitive evaluation was performed for a total of 980 subjects (then aged 69-78 years), and 48 cases with AD were identified. ApoE4 phenotype was more frequently present among subjects with AD. In the whole study population, survival was not related to the presence of AD or ApoE4 phenotype. Risk of death was increased for men compared to women, independently of the ApoE4 phenotype (HR 0.5, 95% confidence interval 0.44-0.69). In subjects with AD, the presence of ApoE4 alone did not influence survival. However, in the AD group, ApoE4-negative men had significantly increased risk of mortality compared to the risk in ApoE4-negative women (p < 0.01). We conclude that the presence of ApoE4 phenotype or AD did not influence mortality in the aged population. Once AD had become manifest, ApoE4 alone did not relate to survival. However, in subjects with AD not carrying ApoE4, men had reduced survival compared to women. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11060507     DOI: 10.1159/000026272

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  8 in total

1.  Apolipoprotein E-related all-cause mortality in hospitalized elderly patients.

Authors:  Maria G Matera; Daniele Sancarlo; Francesco Panza; Carolina Gravina; Grazia D'Onofrio; Vincenza Frisardi; Grazia Longo; Luigi P D'Ambrosio; Filomena Addante; Massimiliano Copetti; Vincenzo Solfrizzi; Davide Seripa; Alberto Pilotto
Journal:  Age (Dordr)       Date:  2010-04-20

2.  Survival in Alzheimer disease: a multiethnic, population-based study of incident cases.

Authors:  E P Helzner; N Scarmeas; S Cosentino; M X Tang; N Schupf; Y Stern
Journal:  Neurology       Date:  2008-11-04       Impact factor: 9.910

3.  Genetic Determinants of Survival in Patientswith Alzheimer’s Disease.

Authors:  Xingbin Wang; Oscar Lopez; Robert A Sweet; James T Becker; Steven T DeKosky; Mahmud M Barmada; Eleanor Feingold; F Yesim Demirci; M Ilyas Kamboh
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

4.  Apolipoprotein E genotype, dementia, and mortality in the oldest old: the 90+ Study.

Authors:  María M Corrada; Annlia Paganini-Hill; Daniel J Berlau; Claudia H Kawas
Journal:  Alzheimers Dement       Date:  2012-11-02       Impact factor: 21.566

5.  Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down syndrome.

Authors:  V P Prasher; S G Sajith; S D Rees; A Patel; S Tewari; N Schupf; W B Zigman
Journal:  Int J Geriatr Psychiatry       Date:  2008-11       Impact factor: 3.485

6.  Apolipoprotein E and mortality in African-Americans and Yoruba.

Authors:  Kathleen A Lane; Sujuan Gao; Siu L Hui; Jill R Murrell; Kathleen S Hall; Hugh C Hendrie
Journal:  J Alzheimers Dis       Date:  2003-10       Impact factor: 4.472

7.  Mediterranean diet and Alzheimer disease mortality.

Authors:  Nikolaos Scarmeas; Jose A Luchsinger; Richard Mayeux; Yaakov Stern
Journal:  Neurology       Date:  2007-09-11       Impact factor: 9.910

8.  Apolipoprotein E gene is related to mortality only in normal weight individuals: the Rotterdam Study.

Authors:  M Carolina Pardo Silva; A Cecile J W Janssens; Albert Hofman; Jacqueline C M Witteman; Cornelia M van Duijn
Journal:  Eur J Epidemiol       Date:  2007-12-28       Impact factor: 8.082

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.